MAGELLAN LONGEVITY
HomeResearchStudy library › Transcutaneous auricular vagus nerve stimulation in patients with…
Study summary · Brain, cognition & mood

Can transcutaneous auricular vagus nerve stimulation (taVNS) improve cognitive functions in patients with mild cognitive impairment (MCI)?

In one paragraph

Vagus Nerve Stimulator, a randomized controlled trial in 52 patients (Brain Stimul 2022, PMID 36150665) — transcutaneous auricular vagus nerve stimulation improved cognitive function and sleep quality in patients with mild cognitive impairment over 24 weeks. Scope: 52 patients, and the abstract states no limitations.

Source: Brain Stimul 2022, PMID 36150665 ↗ · Research map · How Magellan grades evidence · evidence confidence: medium

Brain Stimul · 2022 · PMID 36150665 · DOI 10.1016/j.brs.2022.09.003

Plain-English summary written and published by Magellan Longevity · medical review by Gabriel Radu, DO (physiatrist, NPI 1376861765). We summarize what the paper reported — we did not run this study.

The takeaway

Transcutaneous auricular vagus nerve stimulation improved cognitive function and sleep quality in patients with mild cognitive impairment over 24 weeks.

The question

Can transcutaneous auricular vagus nerve stimulation (taVNS) improve cognitive functions in patients with mild cognitive impairment (MCI)?

What they tested

Transcutaneous electrical stimulation of auricular acupoints in the distribution of the vagus nerve will be effective in improving cognitive functions in patients with MCI.

How they did it

This was a randomized controlled trial involving 52 patients with MCI, aged 55-75 years. Patients were randomly assigned to either a taVNS group, where two auricular acupoints (heart and kidney in the concha) within the vagus nerve distribution were stimulated, or a sham taVNS group, where two other auricular acupoints (elbow and shoulder in the scaphoid fossa) outside the vagus nerve distribution were stimulated. The primary outcome was the Montreal Cognitive Assessment-Basic (MoCA-B), and secondary outcomes included various cognitive and sleep measures. Outcomes were assessed at baseline and after 24 weeks of intervention.

What they found

After 24 weeks, there was a significant difference in overall MoCA-B scores between the taVNS and sham taVNS groups (p = 0.033). In the taVNS group, compared to baseline, overall MoCA-B scores increased significantly (p < 0.001). Specific sub-indicators of the Auditory Verbal Learning Test-HuaShan version (N5 and N7) and Boston Naming Test (BNT) also significantly increased (all ps < 0.001) in the taVNS group. The Shape Trails Test B (STTB) significantly decreased (p = 0.016), and Pittsburgh Sleep Quality Index (PSQI), Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire (RBDSQ), Epworth Sleepiness Scale (ESS), and Functional Activities Questionnaire (FAQ) significantly decreased (p = 0.002, 0.025, <0.001, 0.006 respectively) in the taVNS group. One patient in the taVNS group reported mild, transient adverse reactions.

Significance of Changes in Outcome Measures in taVNS Group
Values shown: P-value
MoCA-B (Overall Scores)0.001
AVLT-H (N5)0.001
AVLT-H (N7)0.001
STTB0.016
BNT0.001
PSQI0.002
RBDSQ0.025
ESS0.001
FAQ0.006

P-values for significant changes in various outcome measures within the taVNS group after 24 weeks of intervention, compared to baseline. Lower p-values indicate stronger statistical significance.

What it means

Transcutaneous auricular vagus nerve stimulation (taVNS) can improve cognitive performance in patients with mild cognitive impairment (MCI). This method may be recommended as a therapy to prevent or prolong the development of MCI into dementia, though further investigation is needed.

Limitations

The abstract does not explicitly state limitations, but it does mention that further investigation is required, implying a need for more research to fully establish the therapy's efficacy and generalizability.

Where the published abstract does not list limitations, we say so rather than inventing them. Read the full paper on PubMed before drawing conclusions.

“taVNS can improve cognitive performance in patients with mild cognitive impairment”— from the published abstract, Brain Stimul 2022

The paper at a glance

TitleTranscutaneous auricular vagus nerve stimulation in patients with mild cognitive impairment: a randomized clinical trial
JournalBrain Stimul
Year2022
PMID36150665 ↗
DOI10.1016/j.brs.2022.09.003 ↗
TopicBrain, cognition & mood

Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗

Where Magellan uses this paper

This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.

Vagus Nerve Stimulator (tVNS)

Improves autonomic balance, anti-inflammatory. Research relevant to this mechanism is indexed on PubMed and linked below; it describes the mechanism rather than this specific product.

Molecules & mechanisms in this paper

Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.

Cite this page

These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.

APA
Magellan Longevity. (2026). Can transcutaneous auricular vagus nerve stimulation (taVNS) improve cognitive functions in patients with mild cognitive impairment (MCI)? [Plain-English summary of Brain Stimul 2022, PMID 36150665, DOI 10.1016/j.brs.2022.09.003]. Magellan Longevity. https://magellanlongevity.com/study/d36150665.html
BibTeX
@misc{magellan_d36150665, title = {Can transcutaneous auricular vagus nerve stimulation (taVNS) improve cognitive functions in patients with mild cognitive impairment (MCI)?}, author = {{Magellan Longevity}}, year = {2026}, howpublished = {\url{https://magellanlongevity.com/study/d36150665.html}}, note = {Plain-English summary of PubMed PMID 36150665; DOI 10.1016/j.brs.2022.09.003; Brain Stimul 2022. Reviewed by Gabriel Radu, DO}, urldate = {2026-08-11} }
Permalink
https://magellanlongevity.com/study/d36150665.html

Related studies in the Magellan library

All 26 Magellan summaries on brain, cognition & mood →

How this summary was made. Every section above restates what the published abstract of PMID 36150665 reports — the question, the design, the numbers, the authors’ own conclusion and their stated limitations. We do not add claims the paper did not make, and we keep negative and no-effect findings in. Magellan’s evidence grades are set from research like this and never from affiliate commissions.

Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →

Educational information, not medical advice. This is a plain-English summary of published research; it is not a treatment recommendation and nothing here is intended to diagnose, treat, cure, or prevent any disease. Individual studies can be wrong, and a single paper rarely settles a question. Talk to your physician before acting on any research, especially if you are pregnant, nursing, or taking medication.